Shares of BioCryst Pharmaceuticals BCRX fell 2% in pre-market trading after the company reported Q1 results.
Earnings per share were up 14.29% over the past year to ($0.24), which beat the estimate of ($0.25).
Revenue of $4,823,000 lower by 18.07% year over year, which beat the estimate of $4,290,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 06, 2020
Webcast URL: https://edge.media-server.com/mmc/p/6c8z23o6
Recent Stock Performance
Company's 52-week high was at $8.15
52-week low: $1.38
Price action over last quarter: down 2.68%
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.